# CorVista Health

> CorVista Health is a medical technology company applying machine learning to cardiovascular diagnostics. Its FDA-cleared CorVista System is a non-invasive, point-of-care device that captures cardiac and hemodynamic signals and analyzes them in the cloud to assess the likelihood of coronary artery disease and pulmonary hypertension - delivering results in minutes, without radiation, contrast, injections, fasting, or exercise. The company aims to shorten the path from symptoms to diagnosis so patients can be treated earlier.

- **Founded:** 2012
- **Headquarters:** Toronto, Ontario, Canada
- **Founders:** Dino Trevisani (Founder (former President & GM, IBM Canada))
- **Team size:** ~25 employees (per Apollo record); leadership and clinical/research teams across Toronto and U.S.
- **Products:** CorVista System, CAD Add-On, Pulmonary Hypertension (PH) Add-On
- **Notable:** FDA 510(k) clearance for the CorVista System with CAD Add-On to assess coronary artery disease, FDA clearance for the Pulmonary Hypertension Add-On (April 2024) - first FDA-cleared machine-learned point-of-care technology for indicating elevated mPAP, FDA Breakthrough Device Designation for the PH Add-On (2022)

## Products & services

- **CorVista System** — A non-invasive, point-of-care cardiovascular diagnostic platform. A capture device records cardiac and hemodynamic signals, which are sent to the cloud-based CorVista Analyzer where proprietary machine-learned algorithms generate results - no radiation, contrast agents, injections, fasting, or exercise required.
- **CAD Add-On** — FDA 510(k)-cleared module that evaluates the likelihood of significant coronary artery disease as an aid in diagnosis.
- **Pulmonary Hypertension (PH) Add-On** — FDA-cleared, FDA Breakthrough-designated module that indicates the likelihood of elevated mean pulmonary artery pressure (mPAP), a marker of pulmonary hypertension - the first machine-learned point-of-care technology for this indication.

## Achievements

- FDA 510(k) clearance for the CorVista System with CAD Add-On to assess coronary artery disease
- FDA clearance for the Pulmonary Hypertension Add-On (April 2024) - first FDA-cleared machine-learned point-of-care technology for indicating elevated mPAP
- FDA Breakthrough Device Designation for the PH Add-On (2022)
- IDENTIFY PH validation study: 82% sensitivity, 92% specificity, >99% negative predictive value
- Raised nearly $100M in total funding, including a $65M Series C in 2021
- Recognized as a Top Medtech Startup (2023)

## Latest updates

- **2024-04** — FDA clears the CorVista System with Pulmonary Hypertension Add-On, the company's second FDA clearance, enabling advanced cardiovascular testing at the point of care.
- **2021-03** — Closes $65M Series C led by Ambix Life Science, bringing total funding to nearly $100M to accelerate product development and commercialization.

## Links

- Website: https://corvista.com
- LinkedIn: http://www.linkedin.com/company/corvista-health
- Twitter/X: https://twitter.com/corvistahealth
- Facebook: https://facebook.com/analytics-4-life-123409871397409

---

Profile page: https://yespress.io/corvista-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-16